JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX) today announced that it has signed a worldwide exclusive license agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem, and Hadasit, the technology transfer company of Hadassah medical organization, for the development and commercialization of BL-4060, a small molecule drug candidate for the treatment of cancer. Financial terms of the license were not disclosed.
